Chr t(4;14)

News alerts, weekly reports and conference planners

Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	Sensitive: B - Late Trials Sensitive : B	Sensitive: B - Late Trials Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B	lenalidomide + isatuximab-irfc Sensitive: B - Late Trials lenalidomide + isatuximab-irfc Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	Sensitive: C2 – Inclusion Criteria Sensitive : C2	Sensitive: C2 – Inclusion Criteria Sensitive : C2
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3	lenalidomide + ixazomib Sensitive: C3 – Early Trials lenalidomide + ixazomib Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3	Proteasome inhibitor + Immunomodulator Sensitive: C3 – Early Trials Proteasome inhibitor + Immunomodulator Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	bortezomib Resistant: C3 – Early Trials bortezomib Resistant : C3	bortezomib Resistant: C3 – Early Trials bortezomib Resistant : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: C3 – Early Trials lenalidomide + elotuzumab Sensitive : C3	lenalidomide + elotuzumab Sensitive: C3 – Early Trials lenalidomide + elotuzumab Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	lenalidomide Sensitive: C3 – Early Trials lenalidomide Sensitive : C3	lenalidomide Sensitive: C3 – Early Trials lenalidomide Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	midostaurin Sensitive: D – Preclinical midostaurin Sensitive : D	midostaurin Sensitive: D – Preclinical midostaurin Sensitive : D
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	PFI-3 Sensitive: D – Preclinical PFI-3 Sensitive : D	PFI-3 Sensitive: D – Preclinical PFI-3 Sensitive : D

Chr t(4;14)

Associations